Larimar Therapeutics Q2 net loss widens to $32.78 million; R&D expenses rise to $28 million
LRMR•Q2 loss widens as spending rises
- Larimar Therapeutics posted a Q2 2026 net loss of USD 32.8 million, or USD 0.30 a share, versus a net loss of USD 26.2 million, or USD 0.41 a share, a year earlier.
- Research and development expense rose 19.86% to USD 28 million, driven by higher manufacturing work and professional fees tied to trials and BLA preparation.
- General and administrative costs climbed 43.55% to USD 6.35 million, on accelerated commercial buildout ahead of a planned mid-2027 launch, if approved.
Cash position and development updates
- Cash, cash equivalents and marketable securities totaled USD 156.3 million at June 30, with cash runway projected into Q3 2027.
- Rolling BLA submission for nomlabofusp is underway with completion expected in 2H 2026; first patient dosing in a global confirmatory Phase 3 study is expected in Q3 2026.
Related News
Kimco Realty lifts annual profit forecast, beats quarterly revenue estimates on strong leasing demand
KIM•
Albany International Q2 FY26 net income more than doubled to USD 17.4 million; net revenues rise 5.8% to USD 329.5 million
AIN•
